lly

It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study confirmed that cancer patients...

It can sometimes be tough to get a straight answer about any potential problems with drugs from the companies that make them, if court records are any guide. AstraZeneca (AZN) told American doctors the company's antipsychotic drug Seroquel didn't cause diabetes, despite alerting Japanese physicians...

AstraZeneca (AZN) has long hoped that its blood-thinner drug Brilinta was going to become a blockbuster. From the looks of things, the company may gets its wish. Back in May, the pharmaceutical company announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis...

Biotechnology company United Therapeutics Corp. (UTHR) announced today it has received a Food and Drug Administration approval for Adcirca, once-a-day 40 mg tablets for the treatment of pulmonary arterial hypertension (PAH). PAH is a progressive, life-threatening disease in which the pressure in a...

If you opened any financial newspaper or site today, you couldn't have missed it: AstraZeneca (AZN) announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis (SNY) and Bristol-Myers Squibb Co's (BMY) blockbuster Plavix in the prevention of cardiovascular events,...

Bank of America Corp. (BAC) did not just manage to avoid a loss in the first quarter, it crushed analysts' expectations, recording earnings of $4.2 billion, or 44 cents per share -- 40 cents higher than the 4 cents a share analysts surveyed by Thomson Reuters expected. But the bank also took a...